alt text alt text

 

DurAVR™

Transcatheter Heart Valve 

BETTER SCIENCE. BETTER DESIGN.

Anteris’ DurAVR™ THV 3D single-piece, native-shaped valve delivers superior performance with the promise of durability – its innovative design is engineered to last the remainder of a patient’s lifetime. The proven benefits of its patented ADAPT® tissue technology, paired with the unique single-piece, native valve shape, valuably positions DurAVR™ valve to deliver a game-changing treatment for patients worldwide with aortic stenosis - providing a needed solution to the challenges physicians are facing today with their patients.

alt text alt text

DurAVR™ THV

ADVANCING TISSUE SCIENCE FOR PERFORMANCE AND DURABILITY

 

DurAVRTM 3D single-piece, shaped valve is designed like the native aortic valve

  • Larger EOA
  • More consistent laminar flow
  • Improved exercise capacity

 

 ADAPT® Anti-calcification Process1

  • Proprietary tissue processing designed to neutralize bovine pericardium tissue to resist calcification
  • Clinical durability with no calcification in over 10 years

 

 

 

 

ComASUR™ Delivery System

 

 

 

 

BUILT FOR PREDICTABILITY



  • Predictable, familiar, steerable balloon expandable delivery and deployment
  • Rotational control for commissural alignment and optimized coronary access
ComASUR

 

REFERENCES

[1] Neethling W, Rea A, Forster G and Bhirangi K (2020) Performance of the ADAPT-Treated CardioCel® Scaffold in Pediatric Patients With Congenital Cardiac Anomalies: Medium to Long-Term Outcomes. Front. Pediatr. 8:198. doi: 10.3389/fped.2020.00198Neethling W, Rea A, Forster G and Bhirangi K (2020) Performance of the ADAPT-Treated CardioCel® Scaffold in Pediatric Patients With Congenital Cardiac Anomalies: Medium to Long-Term Outcomes. Front. Pediatr. 8:198. doi: 10.3389/fped.2020.00198

 

LATEST ANTERIS NEWS

Tile1 TILE1 MOBILE

Breaking News
DurAVR™ THV EFS

US FDA grants DurAVR™ THV
approval for Early Feasibility Study (EFS)

November 2022

ASX Announcement
tile2 Desktop image tile1 mobile

PCR London Valves: Expert Interview

DurAVR THV Impact of Novel Leaflet Design on Hemodynamics and Physiology

Presented by:

Faculty: Bernard Prendergast, MD
Joao Cavalcante, MD, and Chris Meduri, MD
Watch Here
tile3desktop mobtile3

PCR London Valves: Late Breaking Clinical Trial

DurAVR THV First-in-Human Study, 30-day Results
Presented by Chris Meduri, MD
Karolinska University Medical Center, Sweden

 

View Here
tile4 desktop mobtile4

PCR London Valves: Rapid Fire Abstract

DurAVR THV Novel Leaflet Design Restores Aortic Flow and Hemodynamics on Cardiac MRI Analysis
Presented by Pankaj Garg, MD
University of East Anglia, United Kingdom

 

View Here